NeuroSense Therapeutics (NRSN)
Develops PrimeC, a fixed-dose combination therapy for ALS.
Something off on this page? Send us feedback.
Develops PrimeC, an investigational fixed-dose oral combination for ALS, alongside early Alzheimer's and preclinical Parkinson's programs. The company is a pre-commercial clinical-development sponsor, relying on external partners while regulatory approval, financing, and trial execution shape routes to commercialization.
Develops fixed-dose combination therapies for neurodegenerative diseases, centered on PrimeC, an extended-release oral combination of ciprofloxacin and celecoxib for ALS. The broader pipeline includes exploratory Alzheimer's disease work, labeled PrimeC in recent study releases and CogniC on the website, plus preclinical StabiliC work for Parkinson's disease. Operations are based in Israel, with personnel and clinical-development activity extending internationally.
Has advanced PrimeC's manufacturing readiness through external development and manufacturing partners, qualifying suppliers and validating the process. PrimeC has completed PARADIGM and received FDA clearance to initiate the pivotal PARAGON trial, but launch depends on strategic resources. No candidate is approved, and the business has no product revenue or established sales and distribution organization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $166.0K · Total debt $170.0K · Total assets $1.0M · Shareholders' equity −$1.6M
- Revenue
- $0
- Operating income
- −$3.2M
- Net income
- −$3.2M
No dividends on record.
| Institutions13 holders · as of Mar 31, 2026 | ≥ 1.07% | 379.7K ADS | |
| Otherremainder | ≤ 98.93% | 34.97M ADS |
35.35M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutional filings for NRSNW are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Yorkville Advisors Global, LPInstitution | 0.22% | 78,000 ADS | 13Fas of Mar 31, 2026 |
Independent Advisor AllianceInstitution | 0.14% | 50,000 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.14% | 49,096 ADS | 13Fas of Mar 31, 2026 |
Two Sigma Investments, LPInstitution | 0.13% | 44,445 ADS | 13Fas of Mar 31, 2026 |
Meitav Investment House LtdInstitution | 0.11% | 40,000 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Or Eisenberg | officer: Chief Financial Officer | +250,000 | $0.8000 |
| Jun 16, 2026 | Alon Ben-Noon | officer: Chief Executive Officer | +250,000 | $0.8000 |
- Clene
Late-stage CNM-Au8 targets the broad ALS treatment opportunity.
- AllianceBernstein
Masitinib's confirmatory Phase 3 program targets broad ALS care.
- Biogen
Approved Qalsody anchors competition in the SOD1-ALS subset.
- Amylyx Pharmaceuticals
AMX0114 is an active early-stage ALS antisense program.
- Eledon Pharmaceuticals
Tegoprubart retains an ALS option after Phase 2 biomarker work.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeuroSense Therapeutics | $0.4240 | −0.21% | $14.5M | — | — | — | — |
| Clene | $4.19 | +2.07% | $53.2M | — | — | 269.8 | +233.3% |
| AllianceBernstein | $36.63 | −0.11% | $3.41B | 10.8 | 10.1 | 9.9 | +5.1% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Amylyx Pharmaceuticals | $34.85 | +1.01% | $3.83B | — | — | — | — |
| Eledon Pharmaceuticals | $3.15 | +5.53% | $230.8M | — | — | — | — |
| Median | 25.1 | 13.4 | 9.9 | +5.1% |